Article
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2014
Sun Jong-Mu, Lira Maruja, Pandya Kinnari, Choi Yoon-La, Ahn Jin Seok, Mao Mao, Han Joungho, Park Keunchil, Ahn Myung-Ju, Kim Jhingook
Abstract excerpt
OBJECTIVES: Anaplastic lymphoma kinase (ALK) rearrangement is a validated predictive marker to define patients with non-small cell lung cancer (NSCLC) who can benefit from selective ALK inhibitors. Therefore, accurate assessment of its prevalence and clinical characteristics is increasingly important in the treatment of NSCLC. Also, this ALK rearrangement was previously reported to be more common in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.